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A LATENT CLASS MIXED MODEL FOR ANALYZING BIOMARKER TRAJECTORIES 
WITH IRREGULARLY SCHEDULED OBSERVATIONS 
SUMMARY 
This paper considers a latent class model to uncover subpopulation structure for both 
biomarker trajectories and the probability of disease outcome in highly unbalanced 
longitudinal data. A specific pattern of trajectories can be viewed as a latent class in a finite 
mixture. Membership in latent classes is modeled with a polychotomous logistic regression. 
The biomarker trajectories within a latent class are described by a linear mixed model with 
possibly time-dependent covariates and the probabilities of disease outcome are estimated via 
a class specific model. Thus the method characterizes biomarker trajectory patterns to unveil 
the relationship between trajectories and outcomes of disease. The coefficients for the model 
are estimated via a generalized EM algorithm (GEM), a natural tool to use when latent classes 
and random coefficients are present. Standard errors of the coefficients are calculated by 
bootstrapping. The model fitting procedure is illustrated with data from the Nutritional 
Prevention of Cancer trials; we use prostate specific antigen (PSA) as the biomarker for 
prostate cancer and the goal is to examine trajectories of PSA serial readings in individual 
subjects in connection with incidence of prostate cancer. 
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1. INTRODUCTION 
We consider the situation where a group of individuals has been followed for a period of time 
for incidence of a specific disease of interest. At irregular intervals during this period, 
biomarker readings, measured on a continuous scale, were taken from each subject. The goal 
is to use information on disease outcomes, the patterns of serial biomarker readings available 
for the subjects, together with covariates, fixed and time-varying, to discover underlying 
subpopulation structure. The identified subpopulations further our understanding of the 
relationships among the biomarker readings, the covariates and the disease outcomes and can 
form the basis of a prognostic tool for classifying patients. 
Ourcwork was motivated by data from the Nutritional Prevention of Cancer (NPC) trials1• 
Those two trials, the first of which began in 1983, followed 1,736 subjects, some for ten years 
or more. The participants had been randomized into two equal groups -- half receiving a daily 
nutritional supplement of selenium (Se ), the others placebo. Many endpoints were recorded, 
and we shall analyze the incidence of prostate cancer among the 1,229 men in the trial. At 
approximate six-month intervals, blood samples were taken from each subject; however, the 
interval lengths were highly variable. These blood samples were frozen, but later were thawed 
and -analyzed retrospectively for the level of prostate specific antigen (PSA). More details of 
the data set will be presented in Section 4. 
The value of PSA as a biomarker for prostate disease has been documented2• Further 
testing for the suspicion of the presence of a tumor in the prostate is often recommended when 
a single reading of PSA exceeds a cutoff of 4 ng/ml. However, because of between patient 
variability, the sensitivity and specificity of this procedure is poor, leading to many false 
positives and false negatives2• However recent studies have shown that use of a series of PSA 
readings over time can lead to more accurate diagnoses3. Longitudinal biomarkers are 
important for other diseases, such as CD4 T -cell counts for onset of clinical AIDS in HIV + 
patients and AFP (alpha fetoprotein) for hepatocellular carcinoma in hepatitis B carriers and 
patients. with liver cirrhosis. Emir et al4 have looked at CEA ( carcinoembryonic antigen), 
CA15-3 (a MUCl mucin gene product) and TPS (tissue polypeptide specific antigen) as 
longitudinal markers for the progression of breast cancer. We use the methods developed in 
2 
• 
this paper to expose subpopulation structure depending on patterns of PSA readings, prostate 
cancer incidence, and Se and other covariates among the NPC participants. 
Logistic regression can be used to classify individuals when there are known subgroups5, 
but it is not designed for handling longitudinal data. In any case, the subgroups are not 
predefined in our application. Regression tree methodology, such as CART6 is a standard 
nonparametric method that can handle unknown subgroups. However, when applying CART 
to longitudinal data7, there are difficulties accommodating time-varying co variates and 
unequally spaced and highly unbalanced biomarker reading~. In addition, such methods do 
not recognize the distinct roles that biomarker trajectories, covariates and disease outcome 
variable~ play. The same problems afflict the multivariate adaptive regression splines 
approach for longitudinal data (MASAL) of Zhang8. Therefore a parametric modeling 
approach may be advantageous. 
An established method for longitudinal data is the two-stage random effect model of Laird 
and Ware9• This approach does not permit distinct subpopulation structure, which is one of 
our primary interests. Belin and Rubin10 and Rubin and Wu11 used a generalized finite mixture 
model for pre-determined distinct subpopulations to analyze repeated measurement data. 
Peng, Jacobs, and Tanner12' 13 used finite mixtures-of-experts models to estimate both the 
parameters in the component mixture models and the mixture fractions for pattern 
classification. Qu, Tan, and Kutner1\ Hadgu and Qu15 and Yang and Becker16 incorporated 
latent classes in a finite mixture model to uncover the structure of subpopulations. However, 
none of these papers additionally incorporate the outcome data into patterns of longitudinal 
response. In a recent interesting paper, Muthen and Shedden17 do include these features. We 
will generalize their approach to accommodate irregularly spaced longitudinal readings and 
unequal numbers of readings for each subject. The model we present here can also be viewed 
as a generalization of the "mixtures-of-experts" models. Moreover we shall illustrate the 
utility of this model for biomarker and outcome data, specifically obtaining interesting results 
for the PSA and prostate cancer incidence data from the NPC trial. 
In our analysis, we model the association between the longitudinal PSA marker process 
and the outcome of prostate cancer. We discuss the role of selenium and other covariates. 
Three subpopulations emerge from our analysis with interpretable identities -- details are 
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given in Section 4. This application illustrates a flexible, descriptive methodology that is 
suitable· for longitudinal measurements in many situations. 
2. THE LATENT CLASS M~D MODEL 
2.1. General Description of the Model 
The search for subpopulation structure leads us to a model that contains K latent classes, with 
each class representing a subpopulation. We model the probability that a subject belongs to a 
latent class with a polychotomous logistic regression, which we allow to. depend on 
covariafes, X• say, specific to the subject. Each subpopulation has its own model for both the 
biomarker readings, y, and the disease outcome, w. Conditional on a subject being a member 
of a subpopulation, we model the continuous biomarker readings using a Laird and W are9 
style mixed model into which we incorporate time-varying and fixed covariates, x, and 
subject-specific random effects, u, modeled through the design matrix for the random effects, 
z. The probability of disease outcome is also allowed to be latent class specific in order to 
further capture subpopulation structure. In the following subsections we give details of each 
portion of the model. 
2.2. Modeling the Probability of Latent Class Membership 
Let C1~ = ( cu, ... , CiK) 1 have a multinomial distribution, in which i = 1, ... , n is the index for 
subjects, k =1, ... , K is the index for latent classes, and Cik is an indicator of class k for subject 
i. The categorical variables in c; are modeled as a function of co variates x *i=(X•i.z, ... , X•im) 1 , 
which would usually include an intercept term, in a multinomial logistic regression. The 
probability that subject i falls into class k is: 
._ P{ _ 1} _ exp(x;;a k) nile.- Cik- - K ' (1) 
I exp(x;;a j) 
j=l 
where ak is the vector containing the coefficients for class k and aK = 0 . 
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2.3. Modeling Trajectories of the Longitudinal Biomarker 
We have repeated measurements for the continuous biomarker readings, y, which are modeled 
as a linear function of fixed and random effects as: 
(2) 
Here, y; = (y;1 , ••• , Y;r;)', and T; is the number of biomarker readings for the ith subject. The 
T;xp matrix of covariates is denoted x; = (xil, ... ,X;r, )', and will typically include time and 
I 
functions of time. The tth row x;, in X; is the tth vector of covariate values for subject i. 
Covariates for random effects are in z; = (z;1, ... ,z;T: )', which is a T;><q sub-matrix of x; with 
I 
qSp. Here {3 and ui are p and q-dimensional vectors of fixed and random coefficients 
respectively. The error £; is a T;-dimensional vector uncorrelated with other variables, multi-
normally distributed with mean 0 and covariance matrix a 2 I r, • 
I 
The biomarker readings, y; are related to the latent class through the random coefficient u; 
whose mean is class specific. In many longitudinal studies, data are irregularly timed and the 
number of measurements differs among subjects. It is therefore usually difficult to model the 
covariance structure of y;. However, using latent classes and random effects, along with 
independent errors, is a natural way to specify a complicated covariance structure. 
2.4. Modeling the Mean of the Random Coefficients 
The random coefficients u; are assumed to have a distribution whose mean is determined by 
latent class membership through the equation: 
u;= Ac;+ ~;. (3) 
Here A is a qx(K-1) matrix of coefficients, A= (,A .. J, ... Ab ... , AK-J), and Ak is a q-dimensional 
column vector containing the means of the random coefficient u; for latent class k. Given class 
membership for subject i being k, i.e. c;k = 1, we have E(u;) = Ak for k=1, .. ,K-1 and E(u;) = 0 
if subject i is in class K. The vector c; has the first K-1 elements of c; defined in ( 1 ). Also ~; 
is a q-dimensional vector of errors uncorrelated with other variables, multi-normally 
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distributed with mean 0 and common covariance matrix 'P across classes. 
The- model in (2) and (3) captures common characteristics of PSA trajectories within a 
subpopulation through latent classes while accommodating the variability among subjects in 
the same subpopulation through random effects. 
2.5. Modeling the Binary Outcome for a Given Subject 
Let w; denote the binary variable for disease outcome for subject i. It is an indicator of 
whether the ith subject experiences a certain outcome. We assume a class-specific probability 
for disease outcome through binary logistic regression with intercept only as: 
exp(pk) 
gk := P{w; = 11 C;k = 1} = . 
l+exp(pk) (4) 
Here Pk is the log-odds of the occurrence of the outcome for a member of class k. 
2.6. Comments on the Above Model 
The relations in (2) and (3) represent a mixture of normal mixed effects for the continuous 
marker variable y;. Given latent class membership c;, y; and w; are assumed independent; this 
is an important feature of the latent class model and greatly simplifies the modeling 
procedure. However, y; and w; are still marginally correlated since the probability of the 
outcome is class-specific as in (4). Subjects within the same latent class are also correlated 
since their random coefficients come from the same distribution as in (3). 
3. MODEL Ffl'I'ING 
The maximum likelihood method is used to obtain coefficient estimates in the above model. 
Since likelihood equations of the observed data (y, w and x) have very complicated 
expressions, we therefore will use the EM algorithm18 to obtain parameter estimates. Standard · 
errors of the estimates are calculated via the bootstrap method. 
. . 
3.1. Parameter Estimation via the GEM Algorithm 
We view the random coefficient u;'s and the latent class variable c;'s as missing data. Let 
[AlB] denote the conditional probability density of A given B; then the complete-data log-
likelihood, log Lc. can be written as: 
6 
n 
logLc = I,{log[c; lx;]+log[u; lx1,c;]+log[w; lx1,c1]+log[y1 lx1,u1]), (5) 
i=l 
(6) 
(7) 
n n K 
I,log[w; lc;]= I,I,c1k(w1loggk +(1-w1)log(l-gk)) 
i=l i=l k=l 
n K 
= LLC;k(w1pk -log(l+exp(pk))); (8) 
i=l k=l 
~ ~( T T; 2 1 a 1 a ) 
"""log[y1 lx1,u1] =""" -.....!..log(2tr) --logO' --2 (y1 - xw- z1u1) (y1 -xw- z1u1) 
i=l l•l 2 2 20" 
1 ~ 1 ~ 2 1 ~( I I 0 
=- 2 £ .. li log(21t')- 2 £-JTi log a --2 2 £.J Y;Y; -y;x;/3- Y;Z;U; 
i=l i=l (J i=l 
(9) 
Conditioning on the observed data, y; and w;, expectations of the terms involving c; and u; 
in (6)- (9) are calculated in the E-step. Parameter estimates are obtained by maximizing the 
conditional expectations in M-step. One step of the Newton-Raphson method with adjusted 
step length for each iteration in the M-step18 is used to estimate a and pin (6) and (8) because 
the likelihood equations for the two logistic regressions are non-linear and do not have closed 
form maximizers. Hence the algorithm is a generalized EM (GEM), see Appendix A.3.1. For 
A, lJI, f3 and d in (7) and (9), estimates are obtained in standard fashion. The E- and M-steps 
are repeated until differences in values of all the estimates in the consecutive iterations are 
sufficiently small. We used a convergence criterion of 10-4. Detailed calculations of theE- and 
M-steps are described in the Appendix. Our GEM algorithm was implemented in Matlab19• 
Multiple starting values of the parameters were used for the GEM algorithm and we chose the 
solution yielding the highest log-likelihood value for a given number of latent classes. 
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3.2. Calculation of Standard Errors for the Estimates via Parametric Bootstrap 
Using our model assumptions, marker readings y and binary outcome variables w for a 
parametric bootstrap sample were simulated using the fmal estimates from the GEM 
algorithm and covariates x for all the subjects in the original data. The model was then refitted 
to each bootstrap sample by the above GEM algorithm. A total of 200 bootstrap samples were 
so generated, from which standard errors of our parameter estimates were obtained. 
4. APPLICATION TO THE PSA DATA SET 
4.1. Description of the Data Set and the Variables 
PSA is a small protein secreted into the blood by prostate tissue, both normal and malignant. 
The concentration of PSA in the blood varies with the amount of normal prostate tissue, the 
amount of cancer, the location and type of cancer, and the extent of any existing infection or 
inflammation of the prostate. A normal blood PSA value is usually less than 3-4 nglml, and 
may vary with age, but about 20% of men diagnosed with prostate cancer have measured PSA 
levels less than 4 nglml 20• With an elevated PSA reading, an ultrasound, biopsy or other test 
may be recommended by physicians to further evaluate the prostate. However, because other 
conditions such as benign prostatic hyperplasia or prostatitis also can increase PSA levels, a 
single high PSA measurement is not a reliable indicator of prostate cancer. Recently, interest 
has focused on the utility of a series of PSA readings for detecting prostate cancer and 
detennining the appropriate medical attention. 
We use the series of PSA readings obtained from the frozen blood samples of the NPC 
participants and the corresponding prostate cancer outcomes to illustrate our latent class 
mixed model. Recall that in this trial the subjects were randomly assigned to receive daily 
either placebo or a nutritional supplement of Se. Thus we seek to use our methodology to 
discover latent structure in the PSA trajectories and prostate cancer outcomes, depending on 
the Se status of the NPC subjects. The data available consist of treatment assignment (Se or 
placebo), prostate cancer diagnosis date (if any), baseline PSA and Se blood levels, and 
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longitudinal PSA and Se readings recorded at approximate six-month intervals for 1229 men. 
We restrict the data used for our analyses in two ways. First, we detennine the outcome 
(prostate cancer or not) for a subject at 7 years after randomization. Thus we include only 
those observations within 7 years of randomization and before prostate cancer diagnosis. This 
7-year window was chosen to balance the number of longitudinal readings available and the 
number of subjects for whom follow up was complete. Whittemore et al. 21 also used a 7-year 
window in their analyses. Second, we omit observations for which the baseline Se level is 
missing since Se is used as a covariate both in predicting class-membership_ and PSA levels in. 
our model. The resulting data set that we analyze consists of 979 subjects with a highly 
variabl~.number of measurements (range 1-16, median 3) at irregularly spaced intervals. Of 
these 979 men, 74 were not followed for at least seven years, among whom, only 12 were not 
followed for six years. All patients had been followed for more than 5 years and 4 months. 
The variables we include in our model are as follows: the covariate vector X• used to 
predict latent class membership in (1) contains the indicator variable of Se supplementation, 
and the values of age, PSA and Se level at randomization. The longitudinal marker value y in 
(2) is the vector of PSA readings transfonned to log (PSA +I); this transfonnation has also 
been used by Pearson et al. 22 and Whittemore et al 21 • The fixed effects covariate vector x in 
equation (2) contains the indicator of Se supplementation, the value of age, and Se level at 
randomization, and linear and quadratic tenns of visit time expressed in years since entry into 
the trial. The covariates for the random effects in (2), z, also contain years since entry up to 
quadratic terms. Finally, the outcome variable w in (4) is an indicator of prostate cancer 
diagnosis within 7 years of entry. In our data, 49% of subjects are in the Se supplementation 
group. As shown in Table 1, the two treatment groups have similar baseline average values of 
age, .Se and PSA. Also, examination of the longitudinal PSA readings reveals little difference 
between the two groups. Not shown, but as expected, the longitudinal Se levels in the Se 
supplementation group rapidly diverge from those in the placebo group, stabilizing at a higher 
level of approximately 164 nglml while the average Se levels in placebo group remains 
almost the same as that at randomization. 
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Table 1: Average Covariate Values (range) by Treatment Group 
Baseline Variable 
Age at entry, years 
Se level at entry, ng/ml 
PSA level at en , n ml 
4.2. Fitting the Model to the Data 
=479) 
We start from the relatively simple case of a single latent class. Then the model reduces to a 
standard linear mixed model. For models with two or more classes, we proceed as in Section 
3. The maximized log-likelihood values corresponding to the K=l, 2, 3, 4 and 5 latent class 
models'are listed in Table 2. The maximized log-likelihood of the one class model is -1356.2 
--low compared to that of the models with latent classes. Using the deviances from Table 2, 
K=4 appears to be the favored number of latent classes; K=5 yields a non-significant 
improvement. 
Two of the PSA trajectories identified by the four-class model are almost the same in 
terms of trajectory shape (Figure 1) and prostate cancer outcome (Table 3). The three-class 
solution, on the other hand, identifies three distinct PSA trajectories. The obseryed incidence 
of disease is closely matched by both the fit of the three- and four-class solutions. And 
residual plots for the biomarker for both three- and four-class models show adequate fit. 
Details of obtaining these fits and residuals are given in Section 4.4. We report detailed 
calculations for the four-class model. 
Table 2: Log-Likelihood by Number ofLatent Classes, K 
Maximized Deviance Difference in number 
K lo -likelihood chan e* of arameters* 
1 -1356.2 1513.4 36 
2 - 912.7 626.4 27 
3 -672.2 145.4 18 
4 -600.0 1.0 9 
5 - 599.5 
* these values are measured by comparison with the 5-class model 
The four-class solution identifies trajectories classes that we shall label as "Lowl", 
"Low2", "Medium" and "High". Figure 1 shows the fitted biomarker values at half year 
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intervals, calculated for each class using the formula log(1 + PSA) = x/3 + zik and inserting 
average-values for each covariate. PSA was transformed back to the original scale for plotting. 
The "Low 1" and "Low2"classes are characterized by a consistently low PSA level (0.6 and 
1.5 ng/ml respectively) throughout the trial period. The ~stimated percentage of subjects in the 
two "Low" classes are 28% and 46% respectively. Table 3 shows that the "Lowl" and "Low2" 
classes both have the lowest estimated probability of developing prostate cancer (0.1% and 
0.9%). The "Medium" class has a higher PSA level than that of the two "Low" classes 
throughout the-trial~ as evidenced in Figure 1. The PSA level increases slightly oveJ.t time for 
this class and the estimated probability of developing prostate cancer for patients in this class 
(10.9%)is between that for those in the "Low" and the "High" classes. The "High" class has 
the highest PSA level at the beginning of the trial, and the predicted level of PSA increases 
over time. About 56% of members in this class are estimated to develop prostate cancer 
within 7 years (Table 3). For comparison, in the three-class solution, we designate the three 
groups as "Low", "Medium" and "High" (Figure 1, lower panel). The proportion in the "Low" 
class is 65%, which closely matches the proportion of the two "Low" classes in the four-class 
solution. Also, the "Medium" and "High" classes are similar between the three- and four-class 
solutions. 
The estimated incidence probabilities, gk, are calculated by plugging the maximum 
likelihood estimates Pk into equation (4). Similarly, class membership probabilities ftik are 
estimated from (1). Each of the four classes have ftik 's that are nearly one for some of the 
subjects, implying that all the four classes can be identified. 
Tables 3 through 7 list parameter estimates for the four-class model; further discussion of 
the significance of effects is in Section4.5.-In Tables 4 and 6 we use "Low2" as the baseline 
class since it is estimated to contain the largest proportion of subjects - almost half. To 
compare the observed PSA trajectories with the fitted ones in Figure 1, we proportionally 
allocated subjects to the classes using the itik 's. An observed trajectory for each class was 
calculated by a weighted average using the allocated proportions. Figure 2 shows that we have 
four distinct observed trajectories. The trajectory for the "High" class in Figure 2 differs from 
that in Figure 1 because of selection bias: the contributions of the many observations with 
II 
small weights from the other classes become increasingly dominant over time as subjects from 
the "High" class are diagnosed with prostate cancer and are dropped from the analysis. 
Table 3: Estimated Probability for the Binary Outcome (g) & Estimated Class Proportions 
Class g (95% C.I.) p (std. err.) Class proportion 
"Low]" 0.0001 (0.0000, 0.0013) -9.2835 (1.3396) 0.2731 
"Low2" 0.0087 (0.0025, 0.0301) - 4.7350 (0.6433) 0.4606 
"Medium" 0.1092 (0.0726, 0.1610) -2.0993 (0.2288) 0.2256 
"Hi h" 0.5566 (0.3845, 0.7161) 0.2273 (0.3561) 0.0407 
1The deviance change for testing that probabilities of developing prostate cancer are the same 
for all classes is 137.51 over 2 d.f. 
Table 4: Estimated <lk. for Class Membership 
Covariate Deviance chan e Class Estimate Std. Err. 
Intercept 874.43 "Low I" 23.5698 (11.23) 
"Medium" -25.8175 (0.739) 
"High" -55.0802 (15.48) 
Treatment group 4.00 "Low I" -2.2426 (1.734) 
"Medium" -0.2797 (0.569) 
"High" -1.9284 (1.359) 
Age at entry 0.89 "Low I" -0.0607 (0.486) 
"Medium" 0.7685 (0.346) 
"High" 0.3275 (0.847) 
log(PSA+l) at entry 2326.46 "Lowl" -45.6412 (22.01) 
"Medium" 22.6165 (0.390) 
"High" 37.3498 (7.857) 
Seat entry 0.50 "Low]" -5.5612 (4.480) 
"Medium" 1.9841 (0.268) 
"Hi h" 3.6535 (2.733) 
Note: "Low2" is fitted as the baseline class, K. 
-- ... - ·-- . 
Table 5: Estimates for the Fixed Effect Coefficients (/3) and d 
Covariate Estimates (Std.err.) Deviance change 
Intercept 0.7493 (0.0241) 1665.82 
Treatment group (Se supplementation) -0.0264 (0.0173) 0.51 
Age at entry 0.0152 (0.0088) 0.80 
Year since entry (linear) 0.0491 (0.0123) 33.70 
Year since entry (quadratic) -0.0039 (0.0015) 12.23 
Seat entry -0.0879 (0.0126) 4.74 
Estimated d 0.0450 (0.0001) 
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Table 6: Class-specific Mean Difference of Random Effects A from the "Low2" Class 
Trend Deviance chan e Class Estimate Std. err. 
Intercept 2894.7 "Low I" -0.4209 (0.0334) 
"Medium" 0.6783 (0.0335) 
"High" 1.7253 (0.0615) 
Linear 399.9 "Lowl" -0.0137 (0.0129) 
"Medium." -0.0135 (0.0127) 
"High" 0.0571 (0.0248) 
-~- ------ ·~-Quadratic 4.4 "Lowl" 0.0006 (0.0010) 
"Medium" 0.0027 (0.0011) 
"Hi h" -0.0011 (0.0020) 
Table 7: Estimates for the Covariance Matrix 'P of Random Coefficient Means 
(Bootstrapping standard errors in parenthesis) 
Intercept 
Linear 
Quadratic 
Interce t 
0.0442 (0.0096) 
-0.0045 (0.0051) 
-0.43e-5 (0.0001) 
Linear 
-0.0045 (0.0051) 
0.0037 (0.0040) 
-0.80e-4 (0.0005) 
4.3. Characterization of the Latent Classes 
Quadratic 
-0.43e-5 (0.0001) 
-0.80e-4 (0.0005) 
0.27e-5 (0.48e-4) 
In Section 4.2, we described the disease marker trajectories for each latent class. We now tum 
to a description of the latent classes themselves, through both covariate values and marker 
trajectories. Table 8 summarizes covariate values by latent classes, revealing some interesting 
features for covariates in each class. The "High" class has a remarkably low proportion in the 
Se supplementation group (37% ), while the percentage of subjects in the Se supplementation 
group is 49% in the study population. Because this class has the highest estimated probability 
of prostate cancer, this observation supports the hypothesized beneficial effect of Se 
supplementation 1• Also, it is notiCed that subjects in the "Medium" and "High" classes have 
much higher average age at entry than those in the two "Low" classes. All classes have similar 
baseline Se levels. 
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Table 8: Average Covariate Values by Latent Classes 
Latent Classes 
Baseline Variables "Lowl" "Low2" "Medium" "Hi h" 
Age at entry, years 62.0 63.4 67.8 68.7 
Se level at entry, ng/ml 107.6 117.6 117.6 ll5.8 
PSA level at entry, ng/ml 0.42 1.21 3.42 12.54 
Pro ortion in Se. rou 0.45 0.51 0.53 0.37 
4.4. Asst>.ssing Fit of the Model 
Marginal predicted values can be obtained for the observed responses y and w. 
The marginal distribution of y; is a normal mixture with density given by: 
K K 
(y;l Xi] = L[Y; I X; ,cik = 1][c;k = 11 x;] = L NT; (x; .B + Z;Ak, Z; 'Pz; + L:; )7r;k. (10) 
k~ k~ 
The predicted Y; 's (fitted log(PSA+J)) are calculated as estimated weighted means according 
to (10). The residuals of log(PSA+l) versus year are plotted as shown in Figure 3. It can be 
seen that almost all residuals fall within 2 units around 0 indicating adequate fit. 
The marginal distribution of w can be calculated as: 
K K 
P{w; = 1} = L[Y; I X;,C;k = 1][cik = 11 x;] = Lgkrrik. (11) 
k=! k=! 
and thus the marginal fitted value for w can be obtained via: P{ w; = 1} =..!.I ±gk;rik . (12) 
n i=I k=I 
The fitted value of P { w; = 1 } for the 4-class solution is 0.0518, which matches closely the 
observed proportion of prostate cancer 0.0531. 
4.5. Discussion of Significance of Effects for the Model 
The deviance approach is used to assess the significance of a given effect for our 4-class 
solution. The deviance change is twice the difference in the maximized log-likelihood 
between models with and without inclusion of the effect parameters to be assessed. The 
deviance changes are in Tables 3 through 7, alongside the parameter estimates. 
l4 
Among those predictors in X• used for the class membership model (1), Table 4 reveals 
that PSA at entry is significant with estimated coefficients in monotone agreement with the 
group ordering. 
We tum our attention now to the fixed effects for the biomarker trajectory model (2). It 
can be seen from Table 5 that the intercept and time since entry are significant. Again Se 
supplementation is not significant, but is associated with lower PSA readings. And higher 
baseline Se level is significantly associated with lower PSA readings. 
Examination of the--deviances -for the class-specific means of the random coefficient~ iP... 
model (3) reveals that the intercepts and terms of time since entry all vary significantly across 
the latent classes. This means that the PSA level at entry is quite different, as are the patterns 
of PSA readings over time among the four classes (Table 6). The estimated intercepts for the 
"Lowl", "Low2", "Medium" and "High" classes are 0.33, 0.75, 1.43 and 2.47 respectively on 
the log scale (Tables 5 and 6) with an estimated within-class standard deviation of 0.21 ( 'l!l[ 2 
in Table 7). 
Finally, testing the hypothesis that the probability of developing prostate cancer is the 
same for all three classes results in a change in deviance of 137.51 with 2 fewer parameters. 
We infer that chances for the prostate cancer differ greatly among the four classes (Table 3). 
6. Concluding Remarks 
Fitting the model to the PSA data illustrates the explanatory power and flexibility of the latent 
class mixed model. The model fits the data well and is able to uncover subpopulation 
structure. We discussed mainly the four-class solution which identified "Lowl", "Low2", 
"Medium" and "High" as statistically significant latent classes; bow:eyer, for many practical 
purposes, the three-class model may be satisfactory. For this model the PSA trajectory 
patterns are clearly distinct among different classes, as are the estimated probabilities of 
prostate cancer. Since the "High" class has the highest probability of developing prostate 
cancer, the fact that the proportion of patients in the selenium supplement group for the 
"High" class is dramatically lower than other classes supports the hypothesis that selenium 
supplementation is beneficial in prostate cancer prevention 1• Sequential estimation of the n;k 
could be a valuable prognostic tool for classifying subjects. Similar dynamic updating ideas 
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have been developed for simpler longitudinal biomarker models23' 24' 25• Our latent class 
results suggest ways to form prognostic indicators for assessing the risk of prostate cancer for 
individuals. The parametric nature of the model provides explanatory power for the estimates 
and correlation in longitudinal data is more easily taken into account. 
APPENDIX: COMPUTATIONAL FORMULAE 
A.l. The Observed-data Log-likelihood 
By the conditional independence of w andy, the observed-data log-likelihood log L 0 , may be 
expressed as: t, log[y,, w1 I x,] ~ t,lo{t.[y, I x,,c,. ~I][ w, I x,,c,, ~I][ c" =]). 
since [Y; I X;,c;] = Nr, (x;/3 +z;Ac;,z;"¥z;+~;). (13) 
I 
A.2. The E Step -
We need to calculate the conditional expectations of c;k, u;u;, c;c; and u;c; in (6), (7) and (8), 
and the conditional expectation of u; and u;z;z;u; in (9). 
L ·-E( 1.,.. )_[c;k=llx;][Y;.w;lx;,c;k=l] et Pik . - Cik!-"'i. Yi. wi - ~=--_:._....:.=::...!..:....._.!._:.._:_~--=-
[y;,w;lx;] 
= 1r;k[Y; I X;,C;k = l][w; I X;,C;k = 1] 
K 
L1r;k[Y; I X;,C;k = l](w; I X;,C;k = 1] 
k=l 
(15) 
Again, by conditional independence of w andy, and let p; = (pu, ... , PiK-I ) ' . Expectation of 
' ~ 1~ ' 1~ 
C;C; can be calculated as: Ecc: =E(-~C;C; I X;,Y;. w;) =-~diag(p;). 
n i=l 11 i=I 
(16) 
Next, E(u;c; I x;.Y;. w;)needs to be calculated. However, First note that 
(17) 
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And by the properties of conditional probability for bivariate normal variables, we have: 
. ' ' -1 {, -1 ' -1 ) E(ui[y;,c;,x;)=Ac;+\f'z;(z/l'z;+~;) (y;-x;/3-z;Ac;)= v;\'P Ac;+Z;~; (y;-x;/3), (18) 
(19) 
(20) 
E(u;u; I X;,J;, w;) can also be calculated by further conditioning on latent class: 
(21) 
(22) 
To calculate the conditional expectation of (9), we note that: 
ii;: =£ (u;l y;, w;, x;) = Ec (E (u;lc;, y;,xi,)) = v; ('P-1 Ap; + z;~;' (Y; -X; {3) ). (23) 
The last equality follows from (18). And by the properties for expectation of the quadratic 
form of a multivariate normally distributed vector, we have: 
(24) 
A.3. The M Step 
A.3.1 The GEM Algorithm Based on One Newton-Raphson Step 
Insertingp;k, the conditional expectation of c;k in (15) into (6), we get: 
17 
(26) 
where E0 (.) denote expectation conditioning on the observed data y; and w1• We then apply 
Newton-Raphson method to obtain estimate for al"J. The log-likelihood of the complete data 
is increased by choosing a(kJ (0 < a(kJ '5.1) small enough in just one iteration of Newton-
Raphson: (27) 
This then defines a GEM sequence26• Thus, we obtain estimates of a" in (j+ J)th GEM 
iteration as: a~i+l) = a~i> + aU>(trcjj>(l-rcjj>)x.;x:;J-l(tx.;(PfJ) -ref/))). (28) 
l=l l=l 
Similarly, inserting p;~c, the conditional expectation of c;k in (15) into (8), then we can 
easily calculate S(p~c) and I(p~c). Use the scheme in (27), we get: 
p.(.i•11 ~ pjl1 +a1j)(~p"g.(.i1 (1- gF1l f(~P!/1 (w,- g)j)l) · (29) 
A.3.2. TheM-Step for Other Parameters 
Inserting Ecc• Euc• and E1111 calculated in (17), (20) and (22) into (7), we have: 
( n ) nq n 1 n ( 1 ~ - - ) E0 2)og[u; I X;,c;] = --log2rc +-log I qr 1--tr 'f'- (E1111 + AEccA'-2E11cA') 
i=l 2 2 2 
(30) 
Then the estimates of A and If' that maximize (30) are: (31) 
and (32) 
Similarly, plugging u; and E(u;z;z;u;) calculated in (23) and (25) into (9), we get: 
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Then the estimates of f3 and cr2 that maximize (30) are: 
n n 
~ = (Lx;x;)-1Lx;(Y; -z/i;) (34) 
i=l i=l 
and 6 2 = (1/i:r;>f(CY; -x,.~)'(y,. -x,.~ -2z,.u)+E(u;z;z,.u,.)). (35) 
i=l i=l 
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solid line: Class "Low", 
Fitted PSA Trajectories for the 3-Class Solution 
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